← Back
Data updated: Jun 28, 2026
IBSA INST BIO
Pharma Pharmaceuticals
IBSA INST BIO is a pharmaceutical company with 1 FDA-approved products.
2018
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
IBSA INST BIO's Key Drugs
IBSA INST BIO's core commercial portfolio centers on LICART — its most strategically important drugs approved in the last 15 years.
IBSA INST BIO's Recent FDA Approvals
New NDA/BLA approvals for IBSA INST BIO over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
IBSA INST BIO's Therapeutic Areas
Disease areas where IBSA INST BIO has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
IBSA INST BIO Pipeline Snapshot
Active clinical trials for IBSA INST BIO across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • LICART leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2018-12-19
- Latest
- 2026-03-27
- Applications
- 1